Cannabis Science Inc (fka CBIS)

[dade]

An open Letter to CBIS Officers.

I would like to purchase more common stock, averaging down on my substantially negative equity position with Cannabis Science
but before I do that, I would greatly appreciate a response to these simple questions regarding our publicly traded comany

Because of the sensitivity of some of these questions and to protect my interest I have blind carbon copied my council
and have poised these questions to the trading public on an open forum.
Your timely response either private or public will be appreciated.

Questions for CBIS Officers:


1. Does CBIS have any intent or plan of action for capitalizing on California's upcoming Proposition19 vote should it pass as expected?
if so, please describe in specifics.
If not why have you ignored this market; California has paved the way to greatness with it's unofficial most profitable & largest export (ahead of even wine, women and song) being Marijuana. CBIS officers have claimed to be industry leaders with massive foresight and industry knowledge. Please explain why you are not poised within California.

2. In June of 2010 CBIS publicly released the acquisition of Montana Pain Management. Two months later you publicly released that CBIS would pursue legal action against Mr. Rosio for deliberately breaching a non disclosure/non-circumvention agreement.
Have you exhausted this pursuit?
Does Dr. Morales have any interest with CBIS?
Does Mr. Rosio have any interest with CBIS?

3. On feb. 18, 2010, The Vancouver Sun Reported: Banned promoter (Ray Dabney) may soon be back touting penny stocks

Read more: http://www.vancouversun.com/life/Banned+promoter+soon+back+touting+penny+stocks/2579722/story.html#ixzz10n0ZamGq

Is this the same Ray Dabney that Richard Cowan admits to receiving equity / stock advise from?
Is Ray Dabney involved with CBIS in any form?
If so in what capacity?
Does Ray Dabney in any form maintain interest in CBIS?

4. On July 8, 2010 CBIS publicly released the "Acquisition of New 9,500 Square foot Denver facility for researching, Developing, Testing and Producing Medical Cannabis. Since that release shareholders have not received an update regarding this space.
Has CBIS executed a lease or purchase agreement?
If so please offer further details regarding this space, its condition, and if or if not CBIS is operating or improving this space for operations.
Specifics here would be welcomed regarding this as shareholders have sent numerous inquiries that have gone unanswered.

5. A shareholder has recently calculated that CBIS has swapped some 33,888,295 shares of common stock between Aug of 2009 and May 19, 2010
How many shares of common stock has CBIS issued in the period from May 19, 2010 to our current date?
Do the officers of CBIS foresee sustainability at any point, from revenues or profit or activities other than the issuing of shares, that will relief the issuing and dilution of our common stock?

6. Because of the transfer of Title, Ticker, Ownership, and cusip: It is difficult to conclude who or what entity maintains majority interest.
It is assumed that K&D Equity maintains majority interest.
Please clarify;
Who (or what combined group) maintains majority interest in CBIS?

7. On Aug 18, 2010 multiple statements were released by CBIS
A. regarding Rockbrook: Please describe our current working relationship and operations and wether officers are pleased with the agreement that was reached.
Has Rockbrook produced funds per the agreement?
Do we expect to continue our relationship with Rockbrook?
B. regarding Smokefree Innotec: It was publicly released that CBIS was entering into a joint venture agreement with SFIO to develop and market smoke free vaporized medical cannabis pharmaceutical products.
Has the Joint Venture been executed? If so what are the basic terms
Has any progress been made with these smoke free vaporized medical cannabis pharmaceutical products?
If so to what extent?

Thank you for your time and service
The shareholders and Trading Public on our open forum are excited for you response.

Respectfully,